Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth.
The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables.
A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain.
Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. And by doing so, we are reiterating our firm resolve to deliver value and satisfaction.
We partner with several pharma companies, based on expense and profit-sharing model
Early Stage Licensing:
We evaluate your gamut of generic product requirements and provide value-added end-to-end solutions, ranging from API development, method development, formulation development to dossier compilation and submission
We also offer our pipeline of products in the conceptualization stage to partners who have a similar product interest
Late Stage Licensing:
We offer our products in various stages of development, ranging from lab scale developed formulations to ready-to-scale up formulations
We also offer a dynamic go-to-market strategy to partners by providing access to products which are developed and ready for dossier submission, as well as already filed products awaiting approval
Our ready-to-register portfolio is offered to partners for launch in their respective markets. We already have a strong presence in these markets in partnership with concerned local majors, through existing product registrations, those in the pipeline and dossiers under preparation.
We offer our generic products to partners seeking to expand their product portfolio in the Indian market, by leveraging our R&D and manufacturing expertise.